Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8, 230

Inhibitory Effect of Topical Adelmidrol on Antigen-Induced Skin Wheal and Mast Cell Behavior in a Canine Model of Allergic Dermatitis

Affiliations

Inhibitory Effect of Topical Adelmidrol on Antigen-Induced Skin Wheal and Mast Cell Behavior in a Canine Model of Allergic Dermatitis

Santiago Cerrato et al. BMC Vet Res.

Abstract

Background: Adelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory compound palmitoylethanolamide (PEA). Based upon its physicochemical properties, adelmidrol is suitable for topical application. The main objective of the present study was to evaluate the efficacy of a topical adelmidrol emulsion on early and late inflammatory responses in hypersensitive dogs. Repeated intradermal injections of Ascaris suum extract were performed in both lateral thoracic areas of six conscious hypersensitive Beagle dogs, topically treated during 8 consecutive days. Adelmidrol (2%) was applied to one side and vehicle to the other. 24 hours after the last antigen challenge, two biopsies (adelmidrol- and vehicle-treated side) were obtained for each dog at the antigen injection site.

Results: A significant reduction in the antigen-induced wheal areas was observed on the 4th and 7th day of adelmidrol treatment. Moreover, cutaneous mast cell numbers were significantly decreased in biopsies obtained after 8 consecutive days of topical adelmidrol treatment.

Conclusions: The results obtained in the present study show that topical treatment with adelmidrol might represent a new therapeutic tool in controlling the early and late allergic inflammatory skin responses in companion animals.

Figures

Figure 1
Figure 1
Schematic representation of the study timeline.
Figure 2
Figure 2
Mean inhibition percentage (± SEM) (n = 6) of wheal areas induced in conscious hypersensitive Beagle dogs byA.suumextract observed before, on the 4th and 7th day of treatment with adelmidrol 2% or vehicle. **P < 0.01.
Figure 3
Figure 3
Mast cells obtained from Beagle skin biopsies after toluidine blue staining (black arrows). Histological sections from the vehicle-treated side (a) and adelmidrol-treated side (b).

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Nazzaro-Porro M. Azelaic acid. J Am Acad Dermatol. 1987;17:1033–1041. doi: 10.1016/S0190-9622(87)70294-1. - DOI - PubMed
    1. Mastrofrancesco A, Ottaviani M, Aspite N, Cardinali G, Izzo E, Graupe K, Zouboulis CC, Camera E, Picardo M. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Exp Dermatol. 2010;19:813–820. doi: 10.1111/j.1600-0625.2010.01107.x. - DOI - PubMed
    1. Costa B, Comelli F, Bettoni I, Colleoni MP, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139:541–550. doi: 10.1016/j.pain.2008.06.003. - DOI - PubMed
    1. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67:15–19. doi: 10.1124/mol.104.006353. - DOI - PubMed
    1. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet J. 2007;173:23–32. - PubMed

Publication types

LinkOut - more resources

Feedback